FULC · Forms 3, 4, 5
Insider trades at Fulcrum Therapeutics, Inc.
No open-market insider buys or sells at Fulcrum Therapeutics, Inc. in the last 90 days; 10 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for Fulcrum Therapeutics, Inc. (FULC) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Most recent insider filings
No Form 3, 4 or 5 filings for Fulcrum Therapeutics, Inc. in the last 90 days. The latest ones on EDGAR:
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Kevin Tang | 10% owner | Buy | 50,945 | $3.52 | $179K | Form 4 | |
| Kevin Tang | 10% owner | Buy | 116,671 | $3.56 | $415K | Form 4 | |
| Kevin Tang | 10% owner | Buy | 107,377 | $3.56 | $382K | Form 4 | |
| Kevin Tang | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Kevin Tang | 10% owner | Buy | 53,651 | $3.56 | $191K | Form 4 | |
| Kevin Tang | 10% owner | Buy | 75,952 | $3.58 | $272K | Form 4 | |
| Kevin Tang | 10% owner | Buy | 12,966 | $3.54 | $46K | Form 4 | |
| Sonja Banks | Director | Options or other derivatives | Form 4 | ||||
| Katina Dorton | Director | Options or other derivatives | Form 4 | ||||
| Robert J Gould | Director | Options or other derivatives | Form 4 | ||||
| Kate Haviland | Director | Options or other derivatives | Form 4 | ||||
| Rachel K. King | Director | Options or other derivatives | Form 4 | ||||
| James A Geraghty | Director | Options or other derivatives | Form 4 | ||||
| Colin Hill | Director | Options or other derivatives | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.